237P - Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)
| Autor: | Mueller, V., Dank, M., de Ducla, S., Mitchell, L., Schneeweiss, A. |
|---|---|
| Zdroj: | In Annals of Oncology 1 October 2016 27 Supplement 6:vi73-vi73 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|